Novartis Pharmaceuticals Corporation v. Lupin Ltd.
1:12-cv-00595
Overview
Parties
Defendant
Novartis Pharmaceuticals Corporation Operating Company
Represented By
5 Attorneys ListedMcCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
Counter Claimant
Lupin Ltd. Operating Company
Represented By
5 Attorneys ListedPotter Anderson & Corroon, LLP
1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951
Potter Anderson & Corroon, LLP
1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951
Lupin Pharmaceuticals Inc. Operating Company
Represented By
2 Attorneys ListedPotter Anderson & Corroon, LLP
1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951
Potter Anderson & Corroon, LLP
1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 5 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | Asserted | Asserted Patent | View Official Patent → |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| π¬π§ United Kingdom | United Kingdom Counterpart | View Official Patent → | |
| π PCT International (WIPO) | PCT World Application | View Official Patent → |
Novartis Pharmaceuticals Corporation v. Torrent Pharmaceuticals Ltd.
Patents Involved
There are 2 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US6294197
Solid oral dosage forms of valsartan
|
Filed: 1997-06-18
Issued: 2001-09-25
|
Expired (Term Ended)
Expires: 2017-06-18
|
|
|
US8101599
Pharmaceutical composition containing anti-hypertensive agents
|
Filed: 2008-12-18
Issued: 2012-01-24
|
Active (2.1 yrs remaining)
Expires: 2028-12-18
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred β Patent expired. Under 35 U.S.C. Β§ 283, injunctive relief is barred.
Standard Statutory Term β No obviousness-type double patenting noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).